




**Veraflo™**  
Therapy

# Start smart for effective and efficient wound care

3M™ Veraflo™ Therapy with  
the 3M™ Smart Instill™ Feature  
makes it easier than ever  
to initiate therapy




## Delayed healing and wound complications are a significant care and cost burden



**40%**

of all wounds are infected or critically colonized<sup>1</sup>



In the average 500-bed hospital, infected wounds can add 9.58 days in excess length of stay and £28,392\* in excess charges<sup>2</sup>



Costs are expected to increase even more as the population ages and the incidence of comorbid conditions that give rise to wounds increases<sup>3</sup>


\*1 USD = 0.73 £ (Exchange rate as of 21st February 2022)



## A smart start to managing bioburden

The number of microorganisms with which an object is contaminated is referred to as the bioburden.<sup>4</sup>

Bioburden formation is commonly considered to occur in five main stages:<sup>5</sup>



## 3M™ Veraflo™ Therapy helps reduce bioburden through repeated cleansing cycles



### Cleanse

Delivers topical wound solutions that dwell in the wound to help dilute and solubilize infectious material<sup>12</sup>



### Remove


Removes solubilized wound debris and infectious materials under negative pressure to lower bioburden<sup>13</sup>



### Promote

Promotes granulation tissue formation and perfusion to prepare the wound for closure<sup>14</sup>


## Veraflo Therapy: Shown to promote granulation tissue formation in a porcine model



A significant increase in granulation thickness

**43%\***

( $p=0.05$ )




Histological images from a porcine study show a 43% increase in granulation tissue thickness between 3M™ V.A.C.® Therapy with the 3M™ V.A.C.® Granufoam™ Dressing (left) and Veraflo Therapy with the 3M™ V.A.C. Veraflo™ Dressing (right) after 7 days of therapy.<sup>15</sup>

\*Shown to promote granulation tissue formation in porcine studies.


## Veraflo Therapy can help:



**Soften**




**Solubilize**



**Separate**

Instillation and dwell cycle helps to soften, separate, and solubilize thick wound exudate and nonviable tissue.<sup>12</sup>

## Veraflo Therapy (NPWTi-d)



Veraflo Therapy combines the benefits V.A.C.® Therapy with an instillation therapy option featuring both **automated volumetric delivery** of topical wound treatment solutions with a **programmable soak feature** which allows solution to dwell in the wound for thorough contact.

## Veraflo Therapy has demonstrated positive clinical outcomes over standard of care, including traditional NPWT<sup>16</sup>

A systematic review of comparative studies and meta-analysis<sup>16</sup> evaluated the performance of Veraflo Therapy versus control in 13 studies and 720 patients with various wound types. Results of the analysis revealed Veraflo Therapy delivered significant advantages over standard of care.



**>30% fewer surgical debridements<sup>16,17</sup>**

(1.77 debridements vs 2.69,  $p=0.008$ )




Wounds were **2.39 times more likely to close<sup>16</sup>**

( $p=0.01$ )



**>50% reduced length of therapy<sup>16,17</sup>**

(9.88 days vs 21.8 days,  $p=0.02$ )



**Reduced bacterial count from baseline<sup>16</sup>**

Odds were 4.4 times greater ( $p=0.003$ )



**Ready for closure almost twice as fast<sup>16,17</sup>**


(7.88 days vs 14.36 days,  $p=0.003$ )



## Use of Veraflo Therapy can potentially reduce costs versus standard of care

Based upon the meta-analysis by Allen Gabriel, MD et al. an economic model<sup>16</sup> was developed to compare the cost using Veraflo Therapy to traditional wound care options including V.A.C.<sup>®</sup> Therapy.

Despite higher therapy cost of Veraflo Therapy, the reduction in therapy time and required OR visits resulted in a potential savings of 48,5%, or up to £5,626 per patient.<sup>17</sup>



**£5,626**  
in savings per patient

Overall potential cost saving with NPWTi versus control based on fewer OR visits, LOS reduction and shorter therapy.

**Note:** The model uses select study data to provide an illustration of estimates of costs for use of Veraflo<sup>™</sup> Therapy or Standard of Care (Control). This model is an illustration and not a guarantee of actual individual costs, savings, outcomes or results. The facility is advised to use this model as an illustration only to assist in an overall assessment of products and pricing. UK daily cost of inpatient stay based on weighted average of hospital stay according to Annex\_A\_National\_Prices\_and\_National\_Tariff\_Workbook = £431.00; UK Mean cost of OR Debridement based on the average cost of theatre time/minute according to R142X Direct cost/hour by speciality workbook, ISD Scotland Theatre Services = £16.49/minute multiplied by 17.7 minutes to undertake a conventional debridement according to Caputo et al 2008 = £291.87. Adding this to cost of a sharp debridement with lidocaine at a cost of £166.75 according to UK Cost Analysis Model for Leg Ulcer Debridement = Grand Total of £458.62 Reference: <https://www.isdscotland.org/Health-Topics/Finance/Costs/Detailed-Tables/Theatres.asp>; Caputo WJ, Beggs DJ, DeFede JL, Simm L, Dharma H. A prospective randomised controlled clinical trial comparing hydrosurgery debridement with conventional surgical debridement in lower extremity ulcers. Int Wound J 2008;5:288–294.; Roberst et al. Development of a UK Cost Analysis Model for the various methods of debriding leg ulcers. Wounds UK. Volume 15. No2. 2019 file:///C:/Users/AA7GCZZ/OneDrive%20-%203M/Documents/Veraflo/Health%20Economics/development-of-a-uk-cost-analysis-model-for-the-various-methods-of-debriding-leg-ulcers.pdf; Control costs vary widely. Average V.A.C.<sup>®</sup> Therapy daily costs are used to be conservative. Daily Veraflo<sup>™</sup> Therapy cost is an estimate only; individual facility cost may vary.

## Veraflo Therapy with 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing: Stage IV pressure ulcer

A 64-year-old male with multiple comorbidities presented with a stage IV pressure ulcer of the sacrum present for over four years.




### Day 0:

Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing initiated.

**Dwell time:** 1 minute

.....  
**NPWT time:** 30 minutes at -150mmHg

.....  
**Solution:** Saline



### Day 3:

Wound at first dressing change.



## Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing: Chronic wound

A 54-year-old male with hypertension, diabetes mellitus, and Charcot foot was admitted to the hospital with a chronic left-foot wound. Patient is treated with an intravenous antibiotic regime, followed by surgical debridement with excision of necrotic tissue.



### Day 0:

**Dwell time:** 10 minutes

.....  
**NPWT time:** 3.5 hours at -125mmHg

.....  
**Solution:** Vashe® Wound Therapy Solution



### Day 2:

After two days of Veraflo Therapy, the wound bed displays healthy granulation tissue with minimal devitalized tissue or thick slough. V.A.C. Veraflo Cleanse Choice Dressing is changed.

Patient data and photos courtesy of Douglas Duke, DO; Director of Wound Care, Flowers Hospital, Dothan, AL.

**Note:** As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient's circumstances and condition.

## Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing: Traumatic wound

A 33-year-old male amputee with history of tobacco use, anemia, and methicillin-resistant *Staphylococcus aureus* presented with infection of above-the-knee stump. Conservative sharp debridement was performed at the bedside, and oral antibiotics were initiated.



### Day 0:

Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing initiated.

**Dwell time:** 10 minutes


.....  
**NPWT time:** 2 hours at -125mmHg  
.....

**Solution:** Hypochlorous Solution  
(80-100mL)



### Day 3:

Wound after 3 days of Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing.



### Days 6 and 9:

Further granulation tissue and reduction in slough after 6 and 9 days of V.A.C. Veraflo Cleanse Choice Dressing. Veraflo Therapy discontinued and switched to V.A.C.® Therapy.

## Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing: Traumatic wound

Following a boating injury, a 26-year-old female received transfemoral amputation that resulted in soft-tissue defect measuring approximately  $90 \times 45\text{cm}^2$ . Antibiotics were administered throughout the patient treatment period.



### Day 0:

With patient in critical condition and debridement no longer an option, Veraflo Therapy with V.A.C. Veraflo Cleanse Choice Dressing was initiated.

**Dwell time:** 5 minutes

.....  
**NPWT time:** 2 hours at -150mmHg

.....  
**Solution:** Dakin's® Solution




### Day 4:

Wound demonstrated healing at 4 days following initiation of Veraflo Therapy.



### Day 8:

Wound showed absence of devitalized tissue, with increase in vascularity and significant granulation. Veraflo Therapy was transitioned to V.A.C. Veraflo Dressing.



### Day 167:

Patient 167 days after initial injury, taking first steps on a new prosthesis.

Patient data and photos courtesy of Brandon Hill, RN, CWCN, FACCWS;  
Ochsner Louisiana State University Health Shreveport, Shreveport, LA

**Note:** As with any case study, the results and outcomes should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient's circumstances and condition.


## Start smart with V.A.C.® Ultra 4 Therapy System

The only device to provide you with a comprehensive selection of negative pressure solutions from a single convenient pump. Empower your outcomes by creating multiple efficiencies across multiple settings.



### Engage the V.A.C.® Ultra 4 Therapy System to:

- Streamline** → Inventory requirements
- Standardize** → Supply protocols
- Reduce** → The number of SKUs required on the shelf
- Manage** → Training time efficiency
- Help** → Clinicians to respond more quickly to patients switching from one negative pressure solution to another



## Introducing the Smart Instill Feature for Veraflo Therapy

The Smart Instill Feature uses sophisticated software that automates many of the Veraflo Therapy steps and delivers an easier and less time-consuming interaction when initiating instillation therapy:

### Now with the Smart Instill Feature



Automatically determines the volume of topical wound solution to instill



Preprogrammed therapy settings align to global advisory recommendations<sup>18</sup>



Animated troubleshooting, customizable alarm and postpone feature

# Therapy initiation steps with the Smart Instill Feature


Just another reason to start smart with Veraflo Therapy.

Select  
Veraflo Therapy

Select  
Smart Instill  
Feature




Canister Selection



Seal Check  
Automated



Fill Estimation  
Automated



Instillation  
Automated



Confirmation  
Optional Automation



## 3M™ V.A.C. Veraflo Cleanse Choice™ Dressing Kit

- Dressing includes 3 different layers: a contact layer with a pattern of larger through holes and 2 cover layers to provide application options for wounds with varying depths
- Provides ‘mechanical’ movement at the wound surface in combination with cyclic delivery and dwell of topical solutions<sup>2</sup>
- The contact layer in combination with a cover layer captures larger particles to help prevent blockage alarms
- The contact layer and the two cover layers provide enhanced conformability



### Therapy goals:



#### Cleanse

Cleanse wounds when slough or nonviable tissue remains



#### Remove

Remove thick, non-viable tissue and infectious materials



#### Promote

Promote granulation tissue formation



#### Prepare

Help prepare for wound closure





## Strengthening the 3M advantage

With a comprehensive portfolio of advanced wound care solutions 3M is at the forefront of scientific innovation, collaborating with clinical partners to develop proven clinical therapies at every point in the care journey.

Innovations like the Smart Instill Feature and V.A.C. Veraflo Cleanse Choice Dressing demonstrate 3M's commitment.

Transforming outcomes through patient-centric science, 3M is setting high standards across the continuum of care.

## 3M Health Care: Your partner in transforming outcomes

We partner with healthcare professionals globally with a focus on transforming outcomes through patient-centered science. When we combine 3M's science with your expertise, amazing things happen.

### Stewarding Skin



We deliver solutions that help protect, manage and support skin healing, leading to fewer complications, reducing trauma and improving each patient's overall well-being.

### Preventing Complications



From reducing the risk of blood stream infections to providing solutions that address patient and staff safety, we're committed to reducing preventable complications to drive toward better outcomes.

### Restoring Lives



From our negative pressure wound therapies, to our comprehensive line of skin integrity solutions, we are focused on helping you provide the best possible care for your patients

## References:

1. September 2014 Survey, N = 240, Surgeons, Podiatrists, WOCNs and PT.
2. Zhan C, Miller MR. Excess Length of Stay, Charges, and Mortality Attributable to Medical Injuries During Hospitalization. *JAMA*. 2003 October 8; 290(14): 1868-74.
3. Department of Health (DOH). Comorbidities: A framework of principles for system-wide action. London: DOH, 2014. Accessed March 2019 at: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/307143/Comorbidities\\_framework.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/307143/Comorbidities_framework.pdf).
4. Bjarnsholt T, Eberlein T, Malone M, Schultz G. Management of wound biofilm made easy. London: *Wounds International*. 2017; 8(2).
5. A fact a day – biofilms and wound care. Wound Source. 2018. Available at: <https://pages.woundsource.com/woundsource-practice-accelerator-biofilms-and-wound-care/>.
6. Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms: A Common Cause of Persistent Infection. *Science*. 1999; 284 (5418):1318-1322.
7. Davies DG, Geesey GG. Regulation of the Alginate Biosynthesis Gene algC in *Pseudomonas aeruginosa* during Biofilm Development in Continuous Culture. *Appl Environ Microbiol*. 1995; 61(3):860-867.
8. Cicmanec F, Holder IA. Growth of *Pseudomonas aeruginosa* in Normal and Burned Skin Extract: Role of Extracellular Proteases. *Infect Immun*. 1979; 25(2): 477-483.
9. Harrison-Balestra C, Cazzaniga BS, Davis SC, et al. A Wound-Isolated *Pseudomonas aeruginosa* Grows a Biofilm In Vitro Within 10 Hours and Is Visualized by Light Microscopy. *Dermatol Surg*. 2003; 29(6):631-635.
10. Schaber JA, Triffo WJ, Suh SJ, et al. *Pseudomonas aeruginosa* Forms Biofilms in Acute Infection Independent of Cell-to-Cell Signaling. *Infect Immun*. 2007; 75(8):3715-3721.
11. Wolcott RD, Rumbaugh KP, James G, et al. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. *J Wound Care*. 2010; 19(8):320-328.
12. Teot L, Boissiere F, Fluieraru S. Novel foam dressing using negative pressure wound therapy with instillation to remove thick exudate. *Int Wound J*. 2017 Oct;14(5):842-848.
13. Brinkert D, Mazen A, Naud M, Maire N, Trial C, Teot L. Negative pressure wound therapy with saline instillation: 131 patient case series. *Int Wound J*. 2013 Dec;10 Suppl 1:56-60.
14. Gupta S, Gabriel A, Lantis J, Teot L. Clinical recommendations and practical guide for negative pressure wound therapy with instillation. *Int Wound J*. 2016 Apr;13(2):159-174.
15. Lessing C, Slack P, Hong KZ, Kilpadi D, McNulty A. Negative pressure wound therapy with controlled saline instillation (NPWTi): dressing properties and granulation response in vivo. *Wounds*. 2011 Oct;23(10):309-319.
16. Gabriel A, Camardo M, O'Rorke E, Gold R, Kim PJ. Effects of Negative-Pressure Wound Therapy With Instillation versus Standard of Care in Multiple Wound Types: Systematic Literature Review and Meta-Analysis. *Plast Reconstr Surg*. 2021 Jan;147(1S-1):68S-76S.
17. Kim PJ, Lookess S, Bongards C, Griffin LP, Gabriel A. Economic model to estimate cost of negative pressure wound therapy with instillation vs control therapies for hospitalised patients in the United States, Germany, and United Kingdom. *Int Wound J*. 2021;1-7.
18. Kim PJ, Attinger CE, Constantine T, et al. Negative pressure wound therapy with instillation: International consensus guidelines update. *Int Wound J*. 2019;1-13. <https://doi.org/10.1111/iwj.13254>.
19. KCI. The Performance of Dermatac™ Drape as compared to V.A.C.® Drape in Healthy Human Subjects. April 5, 2016. KCI. 2015. Dermatac.01.
20. KCI. Summative User Interface Evaluation Report. March 20, 2018.0000046678.
21. KICG. Dermatac Opportunity Assessment: Qualitative & Quantitative Market Research Final Report. October 8, 2015.
22. Galarza, L. (2019, May). Initial clinical observations using a novel negative pressure wound therapy drape comprised of acrylic and silicone. SAWC Spring, San Antonio, TX.

# 3M™ V.A.C.® Ulta Therapy System ordering information for Veraflo Therapy

Pump & Components	
ULTDEV01	3M™ V.A.C.® Ulta Therapy Unit
ULTLNK0500	3M™ V.A.C. Veralink™ Cassette, 5-pack
ULTDUO0500	3M™ V.A.C. VeraT.R.A.C. Duo™ Tube Set, 5-pack
M8275063/5	500mL Canister with gel for use with 3M™ V.A.C.® Ulta Therapy Unit
M8275093/5	1000mL Canister with gel for use with 3M™ V.A.C.® Ulta Therapy Unit

Kits & Dressings	
ULTVCC05MD	3M™ V.A.C. Veraflo Cleanse Choice™ Dressing, medium, 5-pack
ULTVCC05LG	3M™ V.A.C. Veraflo Cleanse Choice™ Dressing, large, 5-pack
ULTVCL05MD	3M™ V.A.C. Veraflo Cleanse™ Dressing, medium, 5-pack
ULTVFL05SM	3M™ V.A.C. Veraflo™ Dressing, small, 5-pack
ULTVFL05MD	3M™ V.A.C. Veraflo™ Dressing, medium, 5-pack
ULTVFL05LG	3M™ V.A.C. Veraflo™ Dressing, large, 5-pack

**Note:** Specific indications, contraindications, warnings, precautions, and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals.



**KCI Medical Ltd 3M Centre**  
Cain Road,  
Bracknell, RG12 8HT, UK  
Freephone 0800 980 8880  
Email UKCUSTSERV@kci-medical.com  
Web 3M.com/KCI

**KCI Medical Ltd.**  
Unit 6-7, 2050 Orchard Avenue  
City West Business Campus, Citywest,  
Co. Dublin, D24 X897, Ireland  
Freephone 1800 33 33 77  
Email IRCS@kci1.com

© 2022 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. All other marks are property of their respective owners.